GSK.L vs NVS
GSK.L: A global biopharma leader specializing in vaccines and specialty medicines to address complex infectious diseases, HIV, and immune-mediated conditions. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | GSK.L | NVS | Edge |
|---|---|---|---|
| Price as of 2026-08-03 close | £19.10 | $156.11 | |
| Market cap as of 2026-08-06 | n/a | $228.1B | |
| P/E as of 2026-08-06 | n/a | 22.08 | |
| PEG as of 2026-08-06 | n/a | 3.66 | |
| Net margin as of 2026-08-06 | n/a | +22.5% | |
| Gross margin as of 2026-08-06 | n/a | +75.0% | |
| Operating margin as of 2026-08-06 | n/a | +29.9% | |
| ROE as of 2026-08-06 | n/a | +29.9% | |
| ROA as of 2026-08-06 | n/a | +11.1% | |
| Debt / equity as of 2026-08-06 | n/a | 1.18 | |
| Revenue growth (YoY) as of 2026-08-06 | n/a | +3.3% | |
| Dividend yield as of 2026-08-06 | n/a | +3.0% | |
| Beta as of 2026-08-06 | n/a | 1.19 | |
| 1-year return as of 2026-08-03 close | +36.7% | +32.6% | GSK.L higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-03.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.